Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19.
Dougan M, Azizad M, Chen P, et al. medRxiv. 2022. [Epub ahead of print]
Racial and ethnic health disparities related to COVID-19.
Lopez L III, Hart LH III, Katz MH. JAMA. 2021;325(8):719-720.
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. N Engl J Med. 2022;386(6):509-520.
Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants.
Takashita E, Yamayoshi S, Simon V, et al. N Engl J Med. 2022;387(5):468-470.
Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020-August 2021.
Wiltz JL, Feehan AK, Molinari NM, et al. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102.
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health (NIH).
Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals.
Centers for Disease Control and Prevention.
Federal response to COVID-19: monoclonal antibody clinical implementation guide.
Department of Health and Human Services (DHHS).
Test to Treat.
Fact Sheet for Healthcare Providers: Emergency Use Authorization for bebtelovimab.
US Food and Drug Administration (FDA).
Fact Sheet for Healthcare Providers: Emergency Use Authorization of Evusheld™ (tixagevimab/cilgavimab).
Fact sheet for healthcare providers: emergency use authorization for Lagevrio™ (molnupiravir).
Fact sheet for healthcare providers: emergency use authorization for Paxlovid™.
Talking with patients about monoclonal antibodies for COVID-19: tips and frequently asked questions.
Are You Up to Date on COVID-19 Diagnosis and Treatment Guidelines?
Test Your Mastery!
|Faculty:||Eric S. Daar, MD|